Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy

Documenti analoghi

• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  di: Hao Xiong, et al.
  Pubblicazione: (2024)
• Exploration of histone protein γ‐H2AX as a prognostic factor in soft tissue sarcomas and its association with biological behavior, immune cell environment and survival in leiomyosarcoma
  di: Adrian Georg Simon, et al.
  Pubblicazione: (2024)
• Immune checkpoint inhibitors combined with anti‐angiogenic therapy as second‐ or further‐line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers
  di: Tong Chen, et al.
  Pubblicazione: (2025)
• Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors
  di: Christina Schmitt, et al.
  Pubblicazione: (2025)
• Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer
  di: Shinkichi Takamori, et al.
  Pubblicazione: (2025)